Healthcare set to be 'transformed' by genomics

DNA double helix DNA double helix

The future of healthcare, the medical profession and clinical trials in the UK were all subjects for discussion at the Academy of Medical Sciences.

The President, Prof Sir John Bell was there with his successor, Prof Sir John Tooke, who takes over the role tomorrow.

Prof Bell, Regius Chair of Medicine at Oxford University said the impact of genomics would transform the diagnosis and treatment of disease.

We've heard this many times before. Every week the medical journals and media run articles about yet another genetic link to disease being identified. There are plenty of references in my blog. Scientists now have huge numbers of targets for research but there have been very few therapies as a direct consequence - perhaps not surprising given the many years it takes to bring new medicines to market.

Prof Bell said the payback was finally happening and would be the "biggest single change in medicine since the discovery of pathogens in the 19th Century".

He added that an information technology revolution in healthcare was underway. Again, there has been much talk of this in the past, and he admitted he'd been sceptical until recently. He pointed to HES - Hospital Episode Statistics - as a major advance.

These record every 'episode' of admitted patient care in hospitals in England, and provide epidemiologists with a unique resource for tracking the effects of treatments.

Clinical trials

Prof Bell said IT in healthcare would transform the way the role of doctors in the future - something he felt many would be unhappy with. Doctors would have to adapt. "The idea that you are trained as an '-ologist' and do that for 30 years is bananas", he said.

Prof Sir John Tooke, the President-elect, is Head of the School of Life and Medical Sciences and Head of the Medical School at University College London. He said there were "unparalleled opportunities" for medicine from genomics, stem cells and the field of regenerative medicine.

He said we should see the NHS as a "population laboratory" - where the public and patients are encouraged to be involved in clinical trials. "Patients benefit, even when they are in the placebo (dummy) arm of a clinical trial, because of the care they receive and the satisfaction of taking part."

But the number of clinical trials conducted in the UK has fallen. Figures from the Association of the British Pharmaceutical Industry show the UK's global share has fallen from 6% in 2000, to 2% in 2006 and 1.4% in 2010.

Prof Tooke said this was in great part due to the bureaucracy that surrounds regulation, which made it unattractive for industry to conduct trials here. The Academy has recommended streamlining the process which he said the government had accepted.

Fergus Walsh Article written by Fergus Walsh Fergus Walsh Medical correspondent

Defeating cancer, the 'evil genius'

Can we win the war against cancer? Over the past 18 months, Panorama has followed a group of patients on drug trials. Some who'd been given months to live, are keeping cancer at bay for years.

Read full article


This entry is now closed for comments

Jump to comments pagination
  • rate this

    Comment number 5.

    This is just another way of throwing loads of money at an already bloated system that prides itself on profit before patients.
    When the human genome was finally completed in 2003 it was predicted then that all diseases would soon be eradicated. Nothing has happened. Hasn't anyone noticed yet that there is no money in cures? All the profit is in expensive treatments so don't expect ANY cures!

  • rate this

    Comment number 4.

    With problem with antibiotic resistance, bacteriophages have been used to define gene structure & gene regulation. Analysis of bacterial genomes has shown that substantial amt of microbial DNA consists of prophage sequences. A detailed database mining of these sequences offers insights into the role of prophages in shaping the bacterial genome = point of attack against bacteria.

  • rate this

    Comment number 3.

    This is exciting. Just consider the aches & pains of our aging population, & ability to zero-in on the exact problem as well as refined pharmacogenomics. Just consider the suffering of infants who cannot speak & ability to zero-in on the exact problem as well as refined pharmacogenomics.
    Also I see it a a cost-saver: bull's eye each & every time - no more exploratory trial & error.

  • rate this

    Comment number 2.

    Hi-tech is expensive, glamorous and "cutting-edge".
    Giving OAP's dignity and comfort is more expensive but mundane and doesn't attract publicity (the kudos goes to local councils as well!)
    So no contest with todays calibre of politicians!

  • rate this

    Comment number 1.

    Do we really want hi tech medicine when we can't look after the basic needs of our elderly?

    We must get that basics right and properly resourced, first.

    Everyone will die, and if lucky will get old and frail before the end - where is the funding to make this as comfortable as possible?

    Shouldn't the care of the elderly be funded first?



Copyright © 2015 BBC. The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.